Preoperative Predictors of Symptom Improvement After Laparoscopic Fundoplication

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMinia University

About this trial

Laparoscopic fundoplication is the standard operation for gastroesophageal reflux disease (GERD) that does not respond adequately to medication, and it relieves reflux symptoms in most patients who are carefully selected for it. Even so, published studies consistently report that between 10% and 30% of patients continue to have symptoms afterwards, develop troublesome side effects such as difficulty swallowing or bloating, or are dissatisfied with the result. Much of this disappointment reflects who was chosen for surgery rather than any technical fault in the operation: patients whose symptoms are not actually caused by acid reflux predictably gain little benefit from a well-constructed wrap.

Individual factors measured before surgery, such as the amount of acid in the esophagus, the link between symptoms and reflux episodes, the type of symptoms, and how well the patient responded to acid-suppressing tablets, have each been linked to the outcome. However, most of that evidence comes from retrospective studies that used different definitions of success, so it is still unclear which factors matter independently once they are considered together.

This study will follow adults with objectively confirmed GERD who are scheduled for elective laparoscopic fundoplication at Minia University Hospitals. Before surgery, every participant undergoes the same standardized assessment: upper endoscopy, 24-hour pH-impedance monitoring off acid-suppressing medication, high-resolution manometry, measurement of height and weight, and questionnaires covering reflux symptoms, anxiety, depression and physical symptom burden. Participants then complete validated symptom questionnaires again at 1, 3, 6 and 12 months after the operation.

The main measure of success is "responder status" at 12 months, meaning at least a 50% improvement in the total GERD-HRQL symptom score compared with before surgery, supported by the patient's own rating of satisfaction. The investigators will analyze ten factors recorded before surgery to determine which of them independently predict this outcome, and will use the results to build and test a prediction tool that surgeons can apply during preoperative counseling.

The study does not assign any treatment. The type of wrap performed, either a complete (Nissen) or a partial posterior (Toupet) fundoplication, is chosen by the treating surgeon according to a prespecified rule based on esophageal motility, exactly as in routine practice. Taking part involves completing questionnaires and attending the usual follow-up appointments, and adds no additional procedural risk.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 18 years or older.

Objectively documented gastroesophageal reflux disease, defined by at least one of the following: pathological acid exposure on off-PPI 24-hour pH or pH-impedance monitoring; Los Angeles grade C or D esophagitis; biopsy-proven Barrett's esophagus; or a positive symptom-reflux association.

Medically refractory or PPI-dependent disease, troublesome regurgitation, or a symptomatic hiatal hernia, with an elective decision for laparoscopic fundoplication.

Able to provide written informed consent and to complete the study questionnaires.

Disqualifiers

Previous antireflux or other major foregut or esophagogastric surgery.

Achalasia or a major esophageal motility disorder on high-resolution manometry (Chicago Classification version 4.0): absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypercontractile esophagus.

Giant or complex paraesophageal hernia requiring non-standard reconstruction, or a concurrent bariatric or other major intra-abdominal procedure.

Esophageal or gastric malignancy.

Trial population

Consecutive adults with objectively documented gastroesophageal reflux disease who are scheduled for elective laparoscopic fundoplication at a tertiary referral center for foregut surgery. Patients are identified and enrolled at the time of preoperative assessment.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Laparoscopic Nissen fundoplication

    Procedure/Surgery

    Standardized laparoscopic complete 360-degree fundoplication with complete hiatal dissection, preservation of the vagi, circumferential mobilization of the distal esophagus to at least 2.5 cm of tension-free intra-abdominal length, posterior crural approximation, and division of short gastric vessels as required. Performed as part of routine clinical care and observed by the study.

  • Laparoscopic Toupet fundoplication

    Procedure/Surgery

    Standardized laparoscopic posterior partial 270-degree fundoplication using the same hiatal dissection and esophageal mobilization as for the complete wrap. Performed as part of routine clinical care and observed by the study.

Treatment groups

470 Participants
are divided into 2 treatment groups
Group A: Complete (Nissen) fundoplication1 intervention
Group B: Partial posterior (Toupet) fundoplication1 intervention

Trial outcomes

Primary outcomes

1

Responder status: proportion of participants achieving clinically significant symptom improvement

Proportion of participants classified as responders. A responder is a participant with a reduction of at least 50% in the total Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) score relative to baseline, corroborated by the patient's global satisfaction rating. The GERD-HRQL comprises 10 symptom items each scored from 0 (no symptoms) to 5 (symptoms incapacitating), giving a total score from 0 to 50, with higher scores indicating worse reflux-related quality of life, together with a separate global item on satisfaction with present condition. The outcome is analyzed as a binary variable, responder versus non-responder, and modeled against ten prespecified preoperative predictors by multivariable logistic regression with age and sex forced as covariates.

Time frame
12 months after surgery

Secondary outcomes

1

Change from baseline in total GERD-HRQL score

Mean change from baseline in the total GERD-HRQL score. Range 0 to 50; higher scores indicate worse reflux-related quality of life, so a negative change indicates improvement.

Time frame
Baseline and 1, 3, 6 and 12 months after surgery
2

Change from baseline in GerdQ score

Mean change from baseline in the total Gastroesophageal Reflux Disease Questionnaire (GerdQ) score. The GerdQ has 6 items giving a total score from 0 to 18; higher scores indicate a greater burden and likelihood of GERD, so a negative change indicates improvement.

Time frame
Baseline and 1, 3, 6 and 12 months after surgery
3

Discontinuation of antisecretory therapy

Proportion of participants no longer taking any proton-pump inhibitor or histamine-2 receptor antagonist, ascertained by structured medication review.

Time frame
12 months after surgery
4

Resolution of regurgitation

Proportion of participants reporting no troublesome regurgitation, ascertained from the regurgitation items of the GERD-HRQL.

Time frame
2 months after surgery

Other outcomes

1

Normalization of esophageal acid exposure

Exploratory. Among participants who undergo postoperative 24-hour pH-impedance monitoring, the proportion with normalization of esophageal acid exposure, defined as acid exposure time of 4% or less. Analyzed for concordance with subjective responder status.

Time frame
12 months after surgery
2

Performance of the multivariable prediction model

Exploratory. Discrimination of the final multivariable logistic regression model, quantified by the C-statistic and reported both apparent and optimism-corrected by bootstrap resampling with 1,000 replications, together with calibration assessed by calibration plot and the Hosmer-Lemeshow test.

Time frame
At final analysis, after all participants complete 12-month follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.